≥99%
2023788-19-2
4813.45 g/mol
Peptides. Deep Dive
Research-based Podcast
Tirzepatide
How tirzepatide works in research
An average rating of 4.7/5 from verified customer feedback
Tirzepatide
Dual GIP/GLP-1 receptor agonist studied for metabolic regulation and weight management.
- Buy3+for$141.55each andsave 5%
- Buy5+for$134.10each andsave 10%
- Buy10+for$126.65each andsave 15%
Peptides. Deep Dive
Research-based Podcast
Tirzepatide
How tirzepatide works in research
An average rating of 4.7/5 from verified customer feedback
Characteristics
| Property | Value |
|---|---|
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| CAS Number | 2023788-19-2 |
| Molar Mass | 4813.45 g/mol |
| Amino Acid Sequence | 39-amino acid synthetic peptide based on GIP with GLP-1 receptor activity; C-20 fatty di-acid acylation |
| Synonyms | LY3298176, dual GIP/GLP-1 receptor agonist |
| Physical Form | Lyophilized powder |
| Solubility | Soluble in aqueous buffers at physiological pH |
| Organoleptic Profile | White to off-white lyophilized powder; odorless |
| Storage Conditions | Store lyophilized at 2-8°C; protect from light |
| Composition | Lyophilized tirzepatide base |
How is Tirzepatide Used in Research?
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Its 39-amino acid sequence is based on the native GIP sequence with modifications that confer simultaneous GLP-1 receptor agonism. A C-20 fatty di-acid moiety enables albumin binding, extending the half-life to approximately 5 days. This dual incretin receptor engagement represents a novel pharmacological approach that leverages complementary metabolic pathways.
Mechanistically, tirzepatide's GIP receptor agonism is thought to enhance adipose tissue insulin sensitivity, improve lipid metabolism, and potentiate the incretin effect beyond what GLP-1 receptor agonism alone achieves. Preclinical studies suggest GIP receptor activation in the central nervous system may contribute to appetite reduction through distinct neuronal populations from those targeted by GLP-1.
In preclinical models, dual GIP/GLP-1 receptor agonism has demonstrated superior metabolic outcomes compared to selective GLP-1 receptor agonism, including greater improvements in glycemic markers, body weight, and hepatic lipid content. Research continues to explore its effects on cardiovascular markers, hepatic steatosis models, and central nervous system pathways.
This product is supplied in a lyophilized form and requires reconstitution prior to laboratory handling. For research and laboratory use only. Not for human or veterinary consumption.
Areas of Study
Dual Incretin Receptor Pharmacology
Studied as the first dual GIP/GLP-1 receptor agonist, leveraging complementary incretin pathways for synergistic metabolic effects in preclinical models.
Glycemic Regulation
Preclinical research demonstrates enhanced glucose-dependent insulin secretion through simultaneous GIP and GLP-1 receptor activation.
Energy Balance & Adiposity
Investigated in preclinical models for body weight and adiposity reduction through central and peripheral metabolic pathway modulation.
Cardiovascular & Metabolic Markers
Investigated for effects on cardiovascular risk markers including lipid profiles and inflammatory markers in preclinical models.
Hepatic Steatosis
Preclinical research explores effects on liver fat reduction through improved hepatic insulin sensitivity and reduced de novo lipogenesis.
References
- [1]Willard FS, Douros JD, Gabe MBN, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532.
- [2]Coskun T, Sloop KW, Loghin C, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism, 18, 3-14.
- [3]Samms RJ, Coghlan MP, Sloop KW. (2020). How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology & Metabolism, 31(6), 410-421.
Disclaimer: The information provided is for research reference only and does not constitute medical advice. Products are sold strictly for in-vitro research use.
Certificate of Analysis (COA)
Third-Party Verified Quality
Every batch of Tirzepatideis independently tested by an accredited third-party laboratory. Our COAs include HPLC purity analysis, mass spectrometry identity confirmation, and batch-specific lot numbers. We publish these results publicly so you can verify exactly what you're getting.
View Lab ResultsGet the Full Research Guide
“Stillwater BioLabs: Evidence-Based Peptide Research” — our comprehensive guide covering peptide handling, reconstitution best practices, storage protocols, and research methodology. Free for all members.
Free forever. No credit card required. Instant access to research tools, exclusive content, and member pricing.
Related Products
PopularSemaglutide
GLP-1 receptor agonist researched for glycemic control and body weight regulation.
Retatrutide
Triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors for metabolic research.
AOD-9604
A modified fragment of human growth hormone (hGH 177-191) studied for fat metabolism.
Cagrilintide
A long-acting amylin analog studied for appetite regulation and metabolic research.
Frequently Bought Together
Tirzepatide
10mg
$149
Semaglutide
5mg
$99
Retatrutide
10mg
$179
Bundle total
$427